Matthew Stanton
Stock Analyst at Jefferies
(0.12)
# 4,111
Out of 5,056 analysts
7
Total ratings
25%
Success rate
-28.89%
Average return
Main Sectors:
Stocks Rated by Matthew Stanton
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AZTA Azenta | Upgrades: Buy | $30 → $38 | $29.42 | +29.16% | 2 | Oct 30, 2025 | |
| RGEN Repligen | Maintains: Hold | $145 → $135 | $153.06 | -11.80% | 1 | Sep 12, 2025 | |
| CYRX Cryoport | Downgrades: Hold | $20 → $8 | $8.39 | -4.65% | 2 | Aug 7, 2024 | |
| LAB Standard BioTools | Initiates: Buy | $3.25 | $1.24 | +162.10% | 1 | Apr 4, 2024 | |
| BLFS BioLife Solutions | Initiates: Buy | $22 | $24.03 | -8.45% | 1 | Apr 4, 2024 |
Azenta
Oct 30, 2025
Upgrades: Buy
Price Target: $30 → $38
Current: $29.42
Upside: +29.16%
Repligen
Sep 12, 2025
Maintains: Hold
Price Target: $145 → $135
Current: $153.06
Upside: -11.80%
Cryoport
Aug 7, 2024
Downgrades: Hold
Price Target: $20 → $8
Current: $8.39
Upside: -4.65%
Standard BioTools
Apr 4, 2024
Initiates: Buy
Price Target: $3.25
Current: $1.24
Upside: +162.10%
BioLife Solutions
Apr 4, 2024
Initiates: Buy
Price Target: $22
Current: $24.03
Upside: -8.45%